ASCO 2023 | The challenges and potential of triple therapies in non-clear cell RCC

Chung-Han Lee, MD, PhD, from Memorial Sloan Kettering Cancer Center, New York, NY, discusses the challenges and potential benefits of adopting triple therapies for Non-clear cell kidney cancer. He mentions the difficulty in achieving the same dose intensity as doublet therapies with triplets and highlights the issue of overlapping toxicities, which can lead to dose reductions and decreased objective response rates. However, he also emphasizes the promise of long-term durable responses with the addition of ipilimumab in triple combinations. Dr Lee suggests that further research and adjustments in drug combinations and design may be needed to optimize the tolerability and efficacy of triple therapies in kidney cancer. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.